Dupilumab-induced Acanthosis Nigricans
Main Article Content
Keywords
dupilumab, atopic dermatitis, acanthosis nigricans, drug reaction
Abstract
Dupilumab is a human monoclonal IgG4 antibody to interleukin-4 (IL-4) and IL-13 approved for the treatment of moderate-to-severe atopic dermatitis (AD) in patients six months or older. Several cutaneous adverse reactions to dupilumab have been reported, including facial dermatitis and psoriasis. Herein, we present a unique case of dupilumab-induced acanthosis nigricans (AN) in a patient treated for concomitant AD and contact dermatitis, in the absence of other associated conditions or potential culprit medications. The patient had complete resolution of the lesions with discontinuation of medication, and recurrence upon re-initiation of therapy. This case represents a new cutaneous adverse reaction to dupilumab to which dermatologists should be familiar.
References
2. FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis. 2022. https://www.sanofi.com/en/media-room/press-releases/2022/2022-06-07-20-45-00-2458243
3. Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. The Lancet. 2017;389(10086):2287-2303.
4. Mourad AI, Haber RM. Drug-induced acanthosis nigricans: A systematic review and new classification. Dermatol Ther. Mar 2021;34(2):e14794. doi:10.1111/dth.14794
5. Das A, Datta D, Kassir M, et al. Acanthosis nigricans: A review. J Cosmet Dermatol. Aug 2020;19(8):1857-1865. doi:10.1111/jocd.13544
6. Stoner RC, Ophaug S, Simpson E, Hanifin J. Acute Pancreatitis in 2 Adolescent Boys on Dupilumab Therapy for Atopic Dermatitis. Dermatitis. Jan-Feb 01 2021;32(1):e21-e23. doi:10.1097/der.0000000000000651
7. Kurokawa Y, Oikawa Y, Shimada A, Yajima K. Dupilumab-related type 1 diabetes in a patient with atopic dermatitis: a case report. Diabetol Int. Jan 2022;13(1):300-303. doi:10.1007/s13340-021-00526-1
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.